Pluristem to Initiate a Phase I/II Clinical Trial in Muscle Injury

Pluristem to Initiate a Phase I/II Clinical Trial in Muscle Injury

Product Candidate Targets Orthopedic and Sports Injuries, Addresses a
Multi-Billion Dollar Annual Market

HAIFA, Israel, Nov. 14, 2012 (GLOBE NEWSWIRE) -- Pluristem Therapeutics, Inc.
(Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell
therapies, today announced it has initiated a Phase I/II clinical trial to
evaluate the safety and efficacy of its PLacental Expanded (PLX) cells in the
treatment of muscle injury. As previously reported, the Paul Ehrlich Institute
(PEI), the German competent authority in the European Union, has granted the
Company clearance to start the trial which will be conducted at the Klinik für
Orthopadie on the campus of the Charité Universitatsmedizin in Berlin,

"Pluristem considers this clinical trial to be our entry into the orthopedic
and sports medicine markets. The response of the gluteal muscle to our PLX
cells will be an indication for us of how well our cells would help various
muscle injuries," stated Zami Aberman, Chairman and CEO of Pluristem.

Study Summary:

In this Phase I/II trial, the muscle injury studied will be the trauma
sustained to the gluteal buttock muscle that occurs during hip replacement.
The most common type of hip replacement surgery involves splitting the gluteal
muscle to obtain access to the hip joint. Previous muscle injury animal
studies have demonstrated a significant improvement in rehabilitation function
and time by using PLX cells over placebo. The endpoint of this study is to
observe if there is an improvement in the functional recovery of the gluteal
muscle as measured by maximal contraction force.

This randomized, double blinded, Phase I/II trial will evaluate the safety and
efficacy of two doses of PLX cells versus placebo administered via
intramuscular injections directly into the site of the lacerated gluteal
muscle before suturing. The study cohort is comprised of approximately 18
patients equally divided between a high and low dose PLX cell group and
placebo group.

About Pluristem Therapeutics Inc.

Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR) is a leading developer
of placenta-based cell therapies. The Company's patented PLX (PLacental
eXpanded) cells are a drug delivery platform that releases a cocktail of
therapeutic proteins in response to a host of local and systemic inflammatory
and ischemic diseases. PLX cells are grown using the company's proprietary 3D
micro-environmental technology and are an "off-the-shelf" product that
requires no tissue matching prior to administration. Pluristem is focusing on
the use of PLX cells administered locally to treat systemic diseases and
potentially obviating the need to use the intravenous route.

Pluristem has a strong patent portfolio, GMP certified manufacturing and
research facilities as well as strategic relationships with major research

For more information visit and follow Pluristem on Twitter
@Pluristem, the content of which is not part of this press release.

The Pluristem Therapeutics Inc. logo is available at

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of
the "safe harbor" provisions of the Private Securities Litigation Reform Act
of 1995 and federal securities laws. For example, we are using forward looking
statements when we discuss the value of the market our Product Candidate
Targeting Orthopedic and Sports Injuries addresses. These forward-looking
statements are based on the current expectations of the management of
Pluristem only, and are subject to a number of factors and uncertainties that
could cause actual results to differ materially from those described in the
forward-looking statements. The following factors, among others, could cause
actual results to differ materially from those described in the
forward-looking statements: changes in technology and market requirements; we
may encounter delays or obstacles in launching our clinical trials; our
technology may not be validated as we progress further and our methods may not
be accepted by the scientific community; we may be unable to retain or attract
key employees whose knowledge is essential to the development of our products;
unforeseen scientific difficulties may develop with our process; our products
may wind up being more expensive than we anticipate; results in the laboratory
may not translate to equally good results in real surgical settings; our
patents may not be sufficient; our products may harm recipients; changes in
legislation; inability to timely develop and introduce new technologies,
products and applications; loss of market share and pressure on pricing
resulting from competition, which could cause the actual results or
performance of Pluristem to differ materially from those contemplated in such
forward-looking statements. Except as otherwise required by law, Pluristem
undertakes no obligation to publicly release any revisions to these
forward-looking statements to reflect events or circumstances after the date
hereof or to reflect the occurrence of unanticipated events. For a more
detailed description of the risks and uncertainties affecting Pluristem,
reference is made to Pluristem's reports filed from time to time with the
Securities and Exchange Commission.

CONTACT: Pluristem Therapeutics Inc.

         William Prather R.Ph., M.D.
         Sr. VP Corporate Development

         Daya Lettvin
         Director Investor & Media Relations

Pluristem Therapeutics Inc. Logo
Press spacebar to pause and continue. Press esc to stop.